12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ixchelsis, Eli Lilly, Pfizer deal

Ixchelsis said in July it acquired rights to IX-01 from Pfizer in exchange for an undisclosed equity stake. The pharma also is eligible for undisclosed milestones and royalties. The oxytocin receptor (OXTR) antagonist is in development...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >